<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| **MYEL-4**  
*Internal request:*  
In the mention of allogeneic stem cell transplant should it be noted that this modality would generally be reserved for high risk patients and usually only in the context of a clinical trial.  
| Based on data in the noted reference, the NCCN Multiple Myeloma Panel modified footnote "I" to state "Allogeneic stem cell transplant may include nonmyeloablative (mini) following autologous stem cell transplant or fully myeloablative preferably on a clinical trial." | Shah. Biol Blood Marrow Transplant. 2015 Mar 11. pii: S1083-8791(15)00174-3. doi: 10.1016/j.bbmt.2015.03.002. [Epub ahead of print] Review | YES 15 NO 0 ABSTAIN 0 |
| **MYEL-D, page 1 of 2**  
*Internal request:*  
Consider adding bortezomib/cyclophosphamide/dexamethasone as a treatment option for newly diagnosed patients with multiple myeloma who are not transplant eligible.  
| Based on the data in the noted reference, the NCCN Multiple Myeloma Panel has included the regimen bortezomib/cyclophosphamide/dexamethasone as a primary therapy option for patients with multiple myeloma who are not candidates for SCT.  
| Jimenez Zepeda VH, Duggan P, Neri PE, Bahlis NJ. Cyclophosphamide, bortezomib and dexamethasone (CyBORD) is a feasible and active regimen for non-transplant Eligible Multiple Myeloma Patients. Vol. 124; 2014  
| YES 16 NO 0 ABSTAIN 0 |
| **MYEL-D, page 1 of 2**  
*Internal request:*  
Consider adding bortezomib/lenalidomide/dexamethasone as a treatment option for newly diagnosed patients with multiple myeloma who are not transplant eligible.  
| Based on the data in the noted reference, the NCCN Multiple Myeloma Panel has included the regimen bortezomib/lenalidomide/dexamethasone for patients with multiple myeloma who are not candidates for SCT.  
| YES 16 NO 0 ABSTAIN 0 |
| **MYEL-D, page 2 of 2**  
*External Request:*  
Celgene Corporation – Request for Panel consideration to change the recommended use of pomalidomide as a preferred regimen for previously treated multiple myeloma from a Category 2A to a Category 1 recommendation.  
| Based on the data in the noted reference and NCCN Multiple Myeloma Panel consensus, the NCCN category of evidence and consensus for pomalidomide/dexamethasone changed from a category 2A to a category 1 recommendation.  

Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone (Kd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed multiple myeloma (RMM): Results from the phase III study ENDEAVOR. ASCO Meeting Abstracts 2015;33:8509. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/8509.

MYEL-D, page 2 of 2
Internal request: Consider “carfilzomib/dexamethasone” as a preferred therapeutic option for previously treated multiple myeloma.
Based on the data in the noted reference, the NCCN Multiple Myeloma Panel has included the combination of carfilzomib/dexamethasone as an option for patients with relapsed/refractory myeloma.

*A Panel member left the call early.